Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Efficacy of Faricimab in Patients With Subretinal Hyperreflective Material Associated With Type 2 or Mixed Neovascular Membranes Assessed by Multimodal Imaging
Authors not listed
Biobizkaia Health Research Institute · 2026
Abstract
Whose aim is to:
Determine the percentage of patients with resolution of subretinal hyperreflective material (SHRM) at week 16.
This study is intended to be performed in the ophthalmology departments or ophthalmology clinics of the participating sites, located in Spain.
Macular degeneration is an eye disease characterised by progressive damage to the macula leading to a loss of central vision. There are two types of macular degeneration, dry and wet or exudative. The prevalence of the latter in Spain is 1.9% in people aged 65 and over. Among the subtypes of macular neovascularisation (MNV), type 2 is rare (9%), with the majority being mixed type 1 and 2 cases (13.5%). SHRM is present in about 77% of eyes with neovascular age-related macular degeneration (AMD).
Different anti-VEGF (vascular endothelial growth factor) drugs have been used for the treatment of type 2 and mixed 1 and 2 types of MNV. Following treatment, a reduction in SHRM has been observed, although results between studies vary between 34% and 56%. Improvements in best-corrected visual acuity are also achieved in eyes with type 2 MNV with anti-VEGF therapy.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-09 MST
Cite this
APA
Anonymous. (2026). Efficacy of Faricimab in Patients With Subretinal Hyperreflective Material Associated With Type 2 or Mixed Neovascular Membranes Assessed by Multimodal Imaging. <em>Biobizkaia Health Research Institute</em>. https://clinicaltrials.gov/study/NCT07403825
Vancouver
Anonymous. Efficacy of Faricimab in Patients With Subretinal Hyperreflective Material Associated With Type 2 or Mixed Neovascular Membranes Assessed by Multimodal Imaging. Biobizkaia Health Research Institute. 2026.
BibTeX
@misc{anon2026Effica,
title = {Efficacy of Faricimab in Patients With Subretinal Hyperreflective Material Associated With Type 2 or Mixed Neovascular Membranes Assessed by Multimodal Imaging},
author = {Anonymous},
journal = {Biobizkaia Health Research Institute},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
IRCCS San Raffaele 2011
Open access · US-GOV
Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration
BMC Ophthalmology 2007
Open access · CC-BY
TOZAL Study: An open case control study of an oral antioxidant and omega-3 supplement for dry AMD
Genaera Corporation 2004
Open access · US-GOV
A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Novartis Pharmaceuticals 2014
Open access · US-GOV
A Phase IV, Prospective, Open-label, Uncontrolled, European Study in Patients With Neovascular Age-related Macular Degeneration (nAMD), Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to Ranibizumab 0.5mg.
Ophthalmology 2006
Citation only
Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
Chengdu Kanghong Biotech Co., Ltd. 2011
Open access · US-GOV